Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival...
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Seaking AlphaSeeking Alpha / Seaking Alpha 9 hours ago 1 Views
Comments